eligible ages (years): 40.0-80.0,  All  Macular Degeneration for subjects will be a clear diagnosis of Age-related Macular Degeneration (AMD) for controls will be less than five small (< 63 um) hard drusen At least a 20/40 view of the fundus The ability to provide a blood sample, and the absence of  listed We will individuals with ocular diseases that might simulate Age-related Macular Dengeration (AMD) or preclude its diagnosis Those might prior laser photocoagulation, cryopexy, media opacity, and inflammatory diseases It is important for potential control subjects not to exhibit media opacity (e.g., cataract), which will prevent visualization of the macula Also, subjects will be excluded if they exhibit diseases that phenotypically overlap with Age-related Macular Degeneration (AMD) such as drusen or pigmentary disturbance of the retinal pigment epithelium (RPE), or that provided insufficient evidence to diagnose Age-related Macular Degeneration (AMD) In addition, subjects with pattern dystrophies, toxoplasmosis, histoplasmosis, degenerative myopia, central serous chorioretinopathy, or any disease or treatment that would diminish the ability to recognize drusen such as laser photocoagulation, prior retinal detachment surgery, posterior uveitis, and trauma will be excluded


A 56-year old Caucasian female complains of being markedly more sensitive to the cold than most people. She also gets tired easily, has decreased appetite, and has recently tried home remedies for her constipation. Physical examination reveals hyporeflexia with delayed relaxation of knee and ankle reflexes, and very dry skin. She moves and talks slowly.

eligible ages (years): 35.0-60.0,  All  Hypothyroidism Recently diagnosed hypothyroid subject (either during the period, or within the 6 previous months) for whom, data related to the diagnosis is available if the diagnosis was not carried out initially by the investigating doctor Subject, who has given his/her oral consent for participation  Subject included in clinical trial or having participated in a clinical trial during the last 3 months Subject presenting a major and objectifiable risk of not being able to follow-up until the next TSH level (moving, problems encountered during another study, pathology affecting the vital prognosis in the short-term) All contraindications to Lévothyrox


eligible ages (years): 0.538-0.712,  All  Nursing Care Preterm Infant were included according with the Official Mexican Norm -007-SSA2-1993 (1995)  Preterm Infant were not included in case of malformations that involved lost of the cutaneous integrity or in case of severe cardiac congenital disease


eligible ages (years): 18.0-49.0,  All  Phase 1 Safety Study of GelVac™ Nasal Powder H5N1 Influenza Vaccine. able to read and sign Informed Consent Form (ICF) male or female > 18 and < 49 years of age at the time the ICF is signed generally healthy, as determined by medical history and clinical assessment able to attend all scheduled visits and to comply with all trial procedures if female of child-bearing potential, use of an acceptable method of contraception or abstinence for at least 4 weeks prior to the first vaccination through at least four weeks after the second vaccination. Acceptable methods are hormonal birth control or a barrier method with spermicide if female, post menopausal (no menstrual period within the last 12 months), surgically sterile (hysterectomy or tubal ligation), or have a negative urine pregnancy test within 24 hours prior to the time of vaccination  has a known allergy to fruits (e.g., apples, oranges) or pectin and/or pectin by-products (including jams or jellies) has a known allergy to dairy/milk products/lactose is breast-feeding or pregnant or planning on becoming pregnant within 1 month of vaccination has a history of a chronic viral infection (i.e.; Shingles, Herpes Zoster, HIV) has a history of severe allergic reaction following influenza vaccination, systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to a vaccine containing the same substances has a history of demyelinating disease (esp. Guillian-Barre Syndrome) history of Bell's Palsy immunosuppression as a result of underlying illness or treatment use of oral steroids, parenteral steroids, or high-dose inhaled steroids (>800 µg/day of beclomethasone dipropionate or equivalent) within 1 month prior to vaccination use of other immunosuppressive or cytotoxic drugs or radiation therapy within six months prior to vaccination


eligible ages (years): 0.0-5.0,  All  Hypothyroxinemia Gestational age < 32 WG FT4 (5, 6 or 7 days of life) ≤ 0.8 ng/dL TSH (5, 6 or 7 days of life) < 20 mIU/L Written consent from the parents  Maternal thyroid disease FT4 (5, 6 or 7 days of life) > 0.8 ng/dL TSH (5, 6 or 7 days of life) > 20 mIU/L Grade III or IV intracerebral hemorrhage


eligible ages (years): 18.0-80.0,  All  Dyslipidemia Patients >18 years old With Subclinical hypothyroidism defined as serum TSH concentration above 5.0 IU/mL when serum FT4 level is within the reference range With OSA defined as mild OSA: AHI 5 to 15/h; moderate OSA:AHI 15 to 30/h; and severe OSA: AHI greater than 30/h (30) will be enrolled With confirmed sustained subclinical hypothyroidism, thus excluding patients with a temporary condition such as that in recovery from a non-thyroidal illness, measurement of TSH and FT4 will be conducted within four weeks before randomization  Current treatment with Levothyroxine and lipid lowering medications or within two months before randomization Conditions known to cause dyslipidemia e.g. uncontrolled diabetes mellitus (HbA1c >9), alcoholism and some medication use e.g. Estrogens. Glucocorticoids, Retinoids or Interferons Conditions indicating levothyroxine treatment (34); including TSH levels more than 10 mU/l, clear symptoms or signs associated with thyroid failure and not related to OSA . e.g. goiter State of pregnancy, Breast feeding or allergy to levothyroxine


eligible ages (years): 3.0-17.0,  All  Pediatric Solid Organ Transplant Patients Pediatric SOT patients (kidney, liver, heart, lungs, intestine, and/or multi-visceral) Must be at least 6 months after transplant 17 years of age, inclusive Available for duration of study Parent or guardian able to be reached by phone  History of hypersensitivity to previous influenza vaccination or severe hypersensitivity to eggs/egg protein History of Guillian-Barre syndrome Receipt of rituximab within the past one year Rejection treatment with intravenous steroid bolus within 30 days Rejection treatment with monoclonal antibody or antilymphocyte preparation (e.g. Alemtuzumab, Muromonab-CD3, etc.) within 90 days Have any condition that would, in the opinion of the site investigator, place them at an unacceptable risk of injury or render them unable to meet the requirements of the protocol Have any condition that the investigator believes may interfere with successful completion of the study History of received 2011-2012 influenza vaccine Pregnant female History of proven influenza disease after September 1, 2011


eligible ages (years): 0.0-999.0,  All  Hypopituitarism All patients with pituitary hypopituitarism  Unavailability of data


eligible ages (years): 0.5-1.5,  All  Down Syndrome patient with a karyotype demonstrating homogeneous, free or Robertsonian translocation trisomy 21 patient having undergone a cardiac ultrasound not demonstrating any severe heart disease patient aged 6 to 18 months at  congenital hypothyroidism hypothyroidism demonstrated by laboratory tests presenting or having presented hyperthyroidism presenting or having presented leukaemia presenting or having presented West syndrome or any other form of epilepsy or unstable neurological disease presenting or having presented signs of central nervous system distress: stroke, postoperative hypoxia, meningitis) presenting severe heart disease on cardiac ultrasound, with haemodynamic effects presenting non-controlled cardiac arrhythmia Apgar < 7 to 5 min at birth Gestational age < 245 days (35 weeks)


eligible ages (years): 18.0-45.0,  All  Group B Streptococcal Infection pregnant women with positive GBS screening culture at 35-37 weeks of gestation singleton gestation subjects with agreement to abstain from the use of any systemic or intravaginal antibiotic, anti-fungal agents, or any other intravaginal product (i.e., contraceptive creams, gels, foams, sponges, lubricants, douches, etc) throughout the trial period  multiple gestations subjects with impaired immunity , diabetes or other significant disease or acute illness that in the investigator's assessment could complicate the evaluation vaginal or systemic antibiotics or antifungal therapy within 2 weeks of the screening visit


eligible ages (years): 80.0-999.0,  All  Hypothyroidism Males and Females aged 80 years or older Diagnosed with hypothyroidism and treated with Levothyroxine for at least 6 months Living independently in the community All TSH results within the range 0.4 U/L in the 3 months before commencing the study Participant has provided written informed consent for participation in the study, prior to any study-specific procedures  Established dementia and therefore deemed incapable of providing informed consent Other medical conditions which, inthe opinion of the Chief Investigator, would prevent them from participating in the study (for example, end stage cancer, severe chronic health conditions where the patient is housebound) Nursing Homes or Residential Care Home residents Individuals with thyroid cancer: since they require high doses of LT4 to suppress their serum TSH Individuals on 25 mcg dailty of LT4: dose reduction will mean that they stop thyroid replacement treatment Non english speaking individuals Participation in any other investigational trials within the last 3 months Participants prescribed medications that can affect thyroid function (amiodarone, lithium, carbimazole or propylthiouracil) Known or suspected lactose intolerance (this would have implications for the proposed over-encapsulated IMP)


eligible ages (years): 18.0-65.0,  All  Acute Mountain Sickness Healthy adults  History of serious illness Current smoker or Hemoglobin >15.5gm/dL Uncontrolled hypertension


eligible ages (years): 18.0-999.0,  All  Neoplasms Patients must have biopsy-confirmed non-hematological malignancy Patients must be scheduled to receive cytotoxic chemotherapy (adjuvant or metastatic setting), excluding immunotherapy Patients must be of age >=18 years Patients must have an absolute lymphocyte count >= 1,000/mcL immediately prior to influenza vaccination Ability of the patient (or legally authorized representative if applicable) to understand and the willingness to sign a written informed consent document  Patients who have already received the influenza vaccine during the season in which they are considered for will be excluded History of allergic reactions attributed to compounds of similar chemical or biologic composition to the influenza vaccine or egg allergies Previous history of Guillian-Barre syndrome within the previous 6 weeks to influenza vaccination Patients must not be receiving chronic steroid therapy, defined as >= 14 days, unless used as part of a chemotherapy regimen Patients must not be on any other agents that can suppress the immune system Planned concurrent therapy with radiation Uncontrolled illness at time of enrollment or influenza vaccination including, but not limited to, ongoing or active febrile illness Psychiatric illness/social situations that would limit compliance with study requirements Known immunosuppression eg. history of organ transplantation or known human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible because they may not be able to mount an appropriate immune response History of influenza-like illness, defined as a temperature > 37.8 degree C with cough or sore throat starting October 1, 2011 throughout the duration of the study


eligible ages (years): 18.0-40.0,  All  Sprain of Lateral Ligament of Ankle Joint age equal or less than 40 years-old, military subject, acute ankle injury, To have completed and signed the informed consent  contraindications to cryotherapy ( cold allergy, cryoglobulinemia, Raynaud's phenomenon, cutaneous sensory abnormalities, and diabetes mellitus), paracetamol allergy, 4th grade sprains according to the Trevino Classification (with bone wrenching), to take analgesic or anti-inflammatory treatment other than paracetamol


eligible ages (years): 18.0-999.0,  All  Women at Risk of Neonatal Infections Colonize With GBS (Group B Streptococci). Patient having a positive vaginal swab for GBS at the end of pregnancy (PCR +) Patient aged over 18 years Patient who received information and agreeing to sign informed consent Patient affiliated or beneficiary of an insurance  Patient does not speak and does not understand French


eligible ages (years): 18.0-65.0,  All  Primary Hypothyroidism. Patients will be between the ages of 18 to 65 and will have been on levothyroxine for primary hypothyroidism for at least 6 months  Patients will be excluded if they have the following problems: pregnancy, plan for pregnancy in the next 12 months, cardiac disease, especially coronary artery disease, chronic obstructive lung disease, malabsorption disorder, gastrointestinal surgeries, significant renal or liver dysfunction, seizure disorders, thyroid and non-thyroid active cancers, uncontrolled psychosis, psychotropic medication use, steroid use, amiodarone, chemotherapy for cancer, iron supplement more than 325mg per day, carafate/ proton pump inhibitor use, cholestyramine use, and those with recent PCS orders who are expected to move out of the geographic area, age less than 18 years old or older than 65 years old Patients scheduled for deployment will be excluded


eligible ages (years): 8.0-20.0,  All  Down Syndrome Subclinical Hypothyroidism Males and females, ages 8 years Diagnosis of Down syndrome Subclinical hypothyroidism: TSH level between 5 mIU/L, normal T4 Parental/guardian permission (informed consent) and if appropriate, child assent Females who are at least 11 years of age or who are menarchal must have a negative urine/serum pregnancy test Committed to adherence to levothyroxine treatment and study completion  Pregnancy Type 1/Type 2 diabetes Chronic medical conditions or medication use that can affect growth, nutrition, blood glucose, insulin secretion, or thyroid function (such as lithium or certain seizure medications) Current use of levothyroxine or anti-thyroid hormone Cyanotic congenital heart disease, or pulmonary hypertension (as described by last echo report in subjects with CHD), or congenital heart disease considered medically unstable by the study cardiologists


eligible ages (years): 18.0-999.0,  All  Thyroid Cancer Differentiated thyroid cancer treated by thyroidectomy and at least 1 ablation with 131-I > 5 months ago TSH < 4 imU/L  Pregnancy Known metastasis


eligible ages (years): 40.0-75.0,  All  Hypothyroidism Thyroid Diseases Endocrine System Diseases 75 years old Diagnosis of overt or subclinical hypothyroidism in two occasions with a minimum interval period of three months  Pregnant or lactating women Severe hepatic or renal dysfunction Psychiatric disabilities, acute cardiovascular and cerebrovascular diseases, chronic respiratory diseases, familiar hypercholesterolemia, malignancy, cholelithiasis, pancreatitis, bowel diseases and other disorders influencing lipid and bile acid metabolism Taking lipid-lowering agents and other drugs influencing thyroid function, lipid and bile acid metabolism Obviously poor compliance


eligible ages (years): 65.0-999.0,  All  Subclinical Hypothyroidism Depression Community-dwelling patients aged >= 65 years with subclinical hypothyroidism Written informed consent  Subjects currently on Levothyroxine or antithyroid drugs, amiodarone or lithium Recent thyroid surgery or radio-iodine (within 12 months) Grade IV NYHA heart failure Prior clinical diagnosis of dementia Recent hospitalisation for major illness or elective surgery (within 4 weeks) Terminal illness Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption Subjects who are participating in ongoing RCTs of therapeutic interventions (including CTIMPs) Plan to move out of the region in which the trial is being conducted within the next 2 years (proposed minimum follow-up period)


eligible ages (years): 18.0-999.0,  All  Celiac Disease Hypothyroidism Celiac Sprue Malabsorption Patients with the diagnosis of hypothyroidism that require thyroid replacement therapy  Surgical resection of thyroid tissue, neck irradiation, radioactive iodine therapy, prior medical treatment with lithium, methimazole, propylthiouracil, ethionamide, amiodarone, or sunitinib, prior serologic testing for celiac disease


eligible ages (years): 5.0-6.0,  All  Dental Caries attending kindergarten in one of the participating schools must have parental permission  children with severe stomach illness (ex. Crohn's disease, ulcerative colitis, Celiac disease, irritable bowel syndrome, etc.) children with strict dietary restriction (ex. Diabetes)


eligible ages (years): 0.0-999.0,  All  Congenital Hypothyroidism Patient: newborn (0-27 days) or infant (28 days 23 months), or child or adult with congenital hypothyroidism (that is to say with a TSH > 15 mU / ml at screening on filter paper and / or plasma TSH> 10 mU / ml) diagnosed in the first months of life, whatever their age, sex, weight and size Subjects with blood levels of free thyroid hormones (FT3 and FT4) in the standards will be described as having subclinical hypothyroidism If treatment with L-thyroxine could be stopped without relapse (that is to say, always with a TSH <5 mU / ml with different controls), hypothyroidism is said to be transient, whatever the age of discontinuation of treatment No pre or neonatal goitre by palpation or ultrasound thyroid negative perchlorate test (ie decreased rate of iodine captation <10% at 2h injection of perchlorate) when the thyroid gland in place No self-immunity known to thyroid in children with and / or his mother (defined by a antithyroperoxidase antibodies and / or antithyroglobulin) Signature of free and informed consent by the patient or his legal representative Affiliation or enjoying a social security system  Presence of markers antithyroid autoimmunity in children and / or mother (antithyroperoxidase antibodies and / or antithyroglobulin) Pre or neonatal goiter on palpation or ultrasound thyroid Test positive perchlorate (ie salting rate of iodine> 10% at 2 injection perchlorate) Patients of foreign origin returned to their country will be excluded from the study


eligible ages (years): 18.0-999.0,  All  Gullian Barre Syndrome Patients aged >18 years diagnosed with GBS according to NINDS diagnostic Onset of weakness due to GBS is less than 2 weeks ago Patients who are unable to walk unaided for >10 metres (grade >3 on GBS disability scale) Patients who are being considered for or already on IVIg treatment First dose of eculizumab must be started within 2 weeks from onset of weakness and any time during the IVIg treatment period Signed informed consent  Age <18 years Patients who are being considered for, or already on, plasma exchange Pregnancy or lactation Patients show clear clinical evidence of a polyneuropahty caused by e.g. diabetes mellitus (except mild sensory), alcoholism, severe vitamin deficiency, and porphyria Patients received immunosuppressive treatment (e.g. azathioprine, cyclosporine, mycofenolatemofetil, tacrolimus, sirolimus or > 20 mg prednisolone daily) during the last month Patients known to have severe concurrent disease, like malignancy, severe cardiovascular disease, AIDS, severe COPD, TB Inability to comply with study related procedures or appointments during 6 months Any condition that in the opinion of the investigator could increase the patient's risk by participating in the study or confound the outcome of the study Related to the administration of eculizumab Unresoled Neisseria meningitidisinfection of history of meningococcal infection Unsuitable for antibiotic prophylaxis (e.g due to allergy) Known hypersensitivity to eculizumab, murine proteins or to any of the excipients Known or suspected hereditary complement deficiencies Women of child-bearing potential who are unwilling to use effective contraception during treatment and for 5 months after treatment is completed


eligible ages (years): 18.0-80.0,  All  Constipation To be considered eligible for enrolment into the study, subjects must Be able to give written informed consent Be between 18 and 80 years of age Subject has chronic functional constipation according to the Rome III Diagnostic where (f) is mandatory i. Must two or more of the following Straining during at least 25% of defæcations Lumpy or hard stools in at least 25% of defæcations Sensation of incomplete evacuation for at least 25% of defæcations Sensation of anorectal obstruction / blockage for at least 25% of defaecations Manual manœuvers to facilitate at least 25% of defæcations (e.g., digital evacuation, support of the pelvic floor)  Subjects will be excluded from the study if they meet any of the below criteria Are less than 18 and greater than 80 years of age Females are pregnant, lactating or wish to become pregnant during the study Are hypersensitive to any of the components of the test product Have a significant acute or chronic, unstable and untreated disease or any condition which contraindicates, in the investigators judgement, entry to the study Subject has an obstructive or metabolic aetiology for constipation Subject has a history of laxative abuse (greater than the daily dosage recommended on the label for any laxative) Subject has used a probiotic or prebiotic product or a dietary fibre supplement in the 4 weeks prior to the baseline visit Subject has a history of drug and/or alcohol abuse at the time of enrolment Having a condition or have taken a medication that the investigator believes would interfere with the objectives of the study, pose a safety risk or confound the interpretation of the study results


eligible ages (years): 18.0-40.0,  All  Muscle Injury for control subjects [primary target being Reserve Officer Training Corps (ROTC) personnel]: 1) healthy individuals ages 18-40 years; and 2) ankle range of motion for the leg to be tested from 0 degrees of plantarflexion to 30 degrees of plantarflexion  for control subjects (primary target being ROTC personnel): 1) previous history of trauma and/or surgery to the lower extremities that may limit function; 2) neurological, vascular, or cardiac problems that may limit function; 3) diabetes; 4) previous traumatic head injury or post-traumatic stress disorder; 5) a contraindication to MRI e.g.: pacemakers, metal implants which are not MRI compatible, pregnancy, and severe claustrophobia; and 6) currently performing an exercise program that specifically targets the dorsiflexor muscles for subjects with muscle atrophy: 1) individuals ages 18-40 years with an injury to the lower leg requiring immobilization but no surgical intervention; and 2) ankle range of motion for the leg to be tested from 0 degrees of plantarflexion to 30 degrees of plantarflexion for subjects with muscle atrophy: 1) previous history of trauma and/or surgery to the lower extremities, other than the injury for being immobilized, that may limit function; 2) neurological, vascular, or cardiac problems that may limit function; 3) orthopedic conditions affecting the contralateral, uninvolved lower extremity that may limit function; 4) diabetes; 5) previous traumatic head injury or post-traumatic stress disorder; and 6) a contraindication to MRI e.g.: pacemakers, metal implants which are not MRI compatible, pregnancy, and severe claustrophobia


eligible ages (years): 18.0-60.0,  All  Asthma years of age or older Known Asthma The exacerbation is defined as moderate or severe Not currently enrolled as an active participant in another clinical trial of a medical therapy or device The patient or first degree family relative (in cases where the patient is intubated) has authorized his/her consent to participate in this trial. The patient will be asked to give his consent only after initial bronchodilator therapy  years of age or older Known thyroid disorders Subject where thyrotoxicosis is suspected Known heart disease Heart rate > 140


eligible ages (years): 60.0-75.0,  All  Aging Age 18 to 35 years, or 60 to 75 years Body mass index ≤ 27 kg•m2 Ability to sign informed consent Score of ≥26 for Mini-Mental State Exam  Diabetics (plasma glucose concentration >200 mg/dl at 2 hr after oral intake of 75 g glucose) Fasting plasma triacylglycerol concentration above 500 mg/dl Kidney disease Liver disease Bleeding disorders Anaemia (Hb < 13 g/dl in males or < 12 g/dl in females) Endocrine disease (with the exception of well-regulated hypothyroidism) Positive hepatitis or HIV screens Alcohol (CAGE questionnaire; abnormal liver enzyme values) or drug abuse (amphetamines, cocaine, opioids, marijuana) Lipid altering agents


eligible ages (years): 60.0-90.0,  All  Disorder of Aging Aged 60 years; diagnosis of failure / vitamin D, preserved cognitive status, disability accepting participate and are not included in any of the  excluded from the study in the elderly using vitamin D supplements; anticonvulsant drugs or for the treatment of HIV / AIDS; diagnosis of type I diabetes mellitus, nephrotic syndrome, acute or chronic renal failure, liver disease, hypothyroidism, hyperthyroidism, history of cerebrovascular accident (CVA) or acute myocardial infarction (AMI) Vascular past 6 months and chronic consumptive diseases, alcoholic or smoker chronic


eligible ages (years): 18.0-60.0,  All  Multiple Sclerosis, Secondary Progressive written informed consent obtained with Multiple Sclerosis, and with secondary progressive disease course screening Expanded Disability Status Scale (EDSS) score between 4.0 and 6.5 inclusive screening timed 25 foot walk (average of two trials) lof 9 seconds or more  Long QT interval, defined as corrected QT interval of more than 470 msec in men and more than 450 msec in women on baseline ECG Patients with known long-QT syndrome Patients with known ventricular arrhythmia Patients with a known electrolyte disturbance Patients undergoing treatment with drugs that increase the QTc interval Patients undergoing treatment with drugs that inhibit CYP3A4, in particular: Ketoconazole, Fluconazole, Erythromycin, Clarithromycin, Ritonavir Patients with a history of breast cancer or carcinoma in situ Patients with known renal insufficiency Patients with known allergy or other intolerability to domperidone Patients currently using Fampridine or 4-aminopyridine


eligible ages (years): 70.0-999.0,  All  Subclinical Hypothyroidism men and women aged 70 and older TSH between 4.5 and 19.9 mU/L as an outpatient ability to provide informed consent  Laboratory Tests TSH <4.5 mU/L or >20 mU/L on repeat testing at least four weeks later or free T4 level outside the reference range thyroid peroxidase (TPO) antibody positive abnormal liver function tests (LFTs >3 x upper limit of normal) hemoglobin <11 g/dL Surgeries or Procedures thyroid surgery pituitary surgery bariatric surgery bowel resection


eligible ages (years): 18.0-65.0,  All  Latent Hypothyroidism latent hypothyroidism  Factors that Alter Thyroxine and Triiodothyronine Binding in Serum Increased thyroxin-binding globulin Decreased thyroxin-binding globulin Binding inhibitors Inherited Salicylates Pregnancy Androgens Furosemide Neonatal state Anabolic steroids


eligible ages (years): 18.0-100.0,  All  Pancreatic Cancer Newly diagnosed adenocarcinoma of the head, neck, or uncinate process of the pancreas Stage I or II disease Surgically resectable disease (R0 or R1) by spiral CT scan No distant metastases ECOG Performance Status of 0 to 1 Adequate organ function as defined by study-specified laboratory tests Must use acceptable form of birth control Signed informed consent form Willing and able to comply with study procedures  Currently have or have history of certain study-specified heart, liver, kidney, lung, neurological, immune, psychological or other medical conditions Patients with history of any autoimmune disease:inflammatory bowel disease, (including ulcerative colitis and Crohn's Disease), rheumatoid arthritis, systemic progressive sclerosis (scleroderma), systemic lupus erythmatosus (SLE) autoimmune vasculitis (e.g., Wegener's Granulomatosis), CNS or motor neuropathy considered to be of autoimmune origin (e.g., Guillian-Barre Syndrome, Myasthenia Gravis, Multiple Sclerosis) Patients who have been diagnosed with another cancer in the past 5 years (except for superficial bladder cancer, non-melanoma skin cancers, or a low grade prostate cancer not requiring therapy) Patients who have received therapy for pancreatic cancer Using systemically active steroid use Patients who have known history of infection with HIV, hepatitis B, or hepatitis C Patients on home oxygen Patients with oxygen saturation of <92% on room air by pulse oximetry Pregnant or lactating Conditions, including alcohol or drug dependence, or intercurrent illness that would affect the patient's ability to comply with study visits and procedures


eligible ages (years): 18.0-999.0,  All  Prostate Cancer Have metastatic castration-resistant prostate cancer Life expectancy of greater than 3 months ECOG performance status 0 or 2 Age ≥18 years Have measurable disease Patients acceptance to have a tumor biopsy of an accessible lesion at baseline and on treatment if the lesion can be biopsied with acceptable clinical risk (as judged by the investigator) Ability to take oral medication Patients must have adequate organ and marrow function defined by study-specified laboratory tests Must use acceptable form of birth control while on study Ability to understand and willingness to sign a written informed consent document  Known history or evidence of brain metastases Prior chemotherapy for metastatic disease in castration-resistant prostate cancer Had surgery within 4 weeks prior to the first dose of study drug Had radiation, biological, or other investigational cancer therapy within 2 weeks prior to the first dose of study drug Had second-line hormonal therapy within 2 weeks prior to the first dose of study drug Systemic steroids within 1 weeks prior to the first dose of study drug Had prior enzalutamide, ARN-509, or galeterone therapy Have moderate or severe cardiovascular disease Have a history of a seizure Have uncontrolled intercurrent illness, including but not limited to ongoing or active infection, systematic congestive heart failure, unstable angina pectoris, cardiac arrhythmia or psychiatric condition that would limit compliance with study requirements


eligible ages (years): 18.0-65.0,  All  Diabetes Mellitus Healthy or treatment naive type 2 diabetes euthyroid subjects, with a micronodular texture of the thyroid gland Recreationally active With stable body weight and diet during the last two months  Any systemic disease(besides glucose abnormalities) Any medication therapy Diabetic complications


eligible ages (years): 18.0-999.0,  All  Group B Streptococcus Age ≥ 18 years Pregnant women presenting for unplanned obstetrical care at a participating clinical study site Gestational age between 21 6/7 and 36 6/7 weeks Subject has not participated in the study before Subject agrees to complete all aspects of the study and provide informed consent in accordance with applicable regulations Signs and/or symptoms suggestive of preterm labor, whereby the managing clinician suspects preterm labor Uterine contractions (with or without pain) Intermittent lower abdominal pain, dull backache, pelvic pressure Vaginal bleeding during the second and third trimester Menstrual-like intestinal cramping (with or without diarrhea)  Exposure to antibiotics within 1 week prior to enrollment (15) Known GBS bacteriuria at the time of enrollment Prior history of neonatal GBS sepsis


eligible ages (years): 35.0-79.0,  All  Osteoarthritis, Knee Planned unilateral TKA done at Verdun Hospital Capacity to communicate in French or English  Complications during or after the surgery Inability to perform the tests due to other diseases Contraindications to cryotherapy such as Raynaud's disease, cryoglobulinemia, hemoglobinopathy, polyneuropathy associated with temperature sensitivity deficits or allergy to cold


eligible ages (years): 18.0-40.0,  All  Streptococcus B Carrier State Complicating Pregnancy Age: 18 to 40 Origin: Arab Gestational age: 34 to 40  Rupture of membranes Women in active labor who has had one or more vaginal examinations


eligible ages (years): 50.0-64.0,  All  Chronic Obstructive Pulmonary Disease for patients with COPD will be Signed informed consent prior to initiation of study-mandated vaccination Patients with spirometric data in the preceding 18 months confirming the diagnosis of COPD Patients meeting GOLD Classification of Stage C or Stage D COPD Patients 50 years old years old for Healthy participants will be Signed informed consent prior to initiation of study-mandated vaccination No active symptoms of lung disease FEV1/FVC in the normal range > 70% age predicted value  Severe allergy to eggs Severe reaction to past doses of influenza vaccine Guillian-Barre syndrome Currently recieving dialysis Current, active, treatment for cancer History of transplant (allograft) Dementia or Alzheimer's disease diagnosis Prior diagnosis of HIV or AIDS Moderate to severe pulmonary hypertension Serum AST/ALT > 3x the upper limit of normal


eligible ages (years): 17.0-70.0,  All  Cough chronic cough group cough lasting ≥ 8 weeks,characterized by irritating dry cough sensitive to fumes，dust,the odorous and cold air with normal chest x-rays. 4.17-70 years old without smoking history. healty controls group: 1.17-70 years old. 2.without smoking hitory or stop smoking for more than 2 years. 3.without chronic cough. 4.without chronic respiratory diseases. 5.without chronic heart, liver, kidney,and autoimmune disease. 6.with normal chest x-rays. 7.with normal pulmonary ventilation function,and histamine challenge test showed negative result  chronic cough group and healty controls group with respiratory tract infection within 8 weeks with chronic respiratory diseases or severe heart, liver, kidney,and autoimmune disease using Angiotensin-Converting Enzyme Inhibitors(ACEI),bronchodilators,glucocorticosteroid,antihistaminics within one week women during pregnancy or lactation patients with malignant tumours


A 44-year-old man was recently in an automobile accident where he sustained a skull fracture. In the emergency room, he noted clear fluid dripping from his nose. The following day he started complaining of severe headache and fever. Nuchal rigidity was found on physical examination.

eligible ages (years): 18.0-50.0,  All  HIV Infections   Co-existing Condition Patients with the following are excluded Neuropsychological (NP) impairments more severe than described in the Criteria Evidence of nervous system dysfunction being caused by factors other than HIV infection, including history of head trauma, multiple sclerosis, epilepsy, or presence of concurrent central nervous system (CNS) infections or neoplasms, e.g., toxoplasmosis, primary or metastatic CNS lymphoma, progressive multifocal leukoencephalopathy, cryptococcal or other fungal meningitis, and CNS tuberculous infections Lymphoma or other tumor requiring cytotoxic chemotherapy Concurrent Medication Excluded Other antiretroviral agents Patients with the following are excluded AIDS or advanced ARC


eligible ages (years): 18.0-999.0,  All  West Nile Virus In order to participate in this clinical trial, all subjects (or legal representative) must provide written informed consent. Only patients meeting entry will be enrolled. Eligible subjects must fall into one of two categories A. Hospitalized patients greater than or equal to 18 years of age with encephalitis and/or myelitis as defined below New neurologic abnormality Asymmetric extremity weakness without sensory abnormality; or Other neurologic abnormality (including altered level of consciousness, dysarthria and dysphagia) plus fever (subjective or objective) within the previous 4 days AND CSF examination within the previous 96 hours showing Absence of organism on gram or fungal stain White blood cell count greater than or equal to 4 per mm(3) corrected for significant red blood cell contamination Ratio of CSF: plasma glucose of greater than or equal to 40% (CSF glucose/plasma glucose greater than or equal to 0.4)  Unable to obtain valid informed consent History of intolerance (including anaphylaxis) to IVIg or related compounds Known history of IgA deficiency Known history of hypersensitivity to maltose History of (or at time of study entry) hyperviscosity syndrome including but not limited to Waldenstrom's macroglobulinemia Multiple myeloma Total white blood cell count greater than 80,000/mm(3) Hematocrit greater than 55% Platelet count greater than 700,000/mm(3)


eligible ages (years): 18.0-50.0,  All  HIV Infections HIV uninfected At low risk for HIV infection Willing to receive HIV test results Good general health Acceptable methods of contraception for females of reproductive potential Hepatitis B surface antigen negative Anti-hepatitis C virus antibody (anti-HCV) negative or negative HCV PCR if anti-HCV is positive Meets educational requirements of the study  HIV vaccines or placebos in prior HIV vaccine trial Immunosuppressive medications within 168 days prior to first study vaccine administration Blood products within 120 days prior to first study vaccine administration Immunoglobulin within 60 days prior to first study vaccine administration Live attenuated vaccines within 30 days prior to first study vaccine administration Investigational research agents within 30 days prior to first study vaccine administration Subunit or killed vaccines within 14 days prior to first study vaccine administration Allergy treatment with antigen injections within 30 days prior to first vaccine administration Current tuberculosis prophylaxis or therapy Serious adverse reaction to a vaccine. A person who had an adverse reaction to pertussis vaccine as a child is not excluded


eligible ages (years): 17.0-65.0,  All  Spinal Cord Injuries Injured subjects Complete or incomplete acute SCI between C0 and T11 Admitted within 48 hours of injury Undergoing spinal decompressive surgery Undergoing lumbar puncture for spinal anesthetic or myelography Neurologically intact  Pre-existing neurodegenerative disorder Associated head or spine injury


eligible ages (years): 18.0-999.0,  All  Pneumococcal Meningitis Adults (> 18 yr) with suspicion of pneumococcal meningitis requiring intensive care unit  Allergy to one of the antibiotics used in the study


eligible ages (years): 18.0-999.0,  All  HIV Infections Lymphoma, AIDS-Related Adult (18 years old or older) HIV-infected patient HIV infected by OraQuick rapid test using saliva, venipuncture whole blood, or fingerstick whole blood; or by reactive ELISA and Western Blot as determined by an outside CLIA-approved laboratory facility or by NIH Clinical Pathology Laboratory or SAIC-Frederick Inc Monitoring Laboratory. HIV infection as determined by an outside CLIA-approved laboratory facility will be verified by a standard HIV-1 ELISA with Western Blot confirmation prior to brain biopsy Evidence of contrast-enhancing focal brain lesion(s) as seen on MRI or CT Willingness to give informed consent and provided by Durable Power of Attorney. In the event that no Durable Power of Attorney has been designated and the patient is unable to do so, the NIH Ethics Committee will be consulted. All patients must designate a Durable Power of Attorney in order to participate in the study Willingness to undergo the procedures involved in the diagnostic evaluation: lumbar puncture, FDG-PET scan, 201Tl-SPECT scan, and brain biopsy Permit the storage of blood, CSF, and tissue samples for future research use Willingness to undergo HLA testing  Previous PCNSL History of prior malignancy other than PCNSL unless in remission for 1 year or longer; non-melanoma skin cancer and Kaposi's sarcoma excepted History of previous diagnosis of toxoplasmic encephalitis or other CNS infection causing focal contrast-enhancing brain lesions Pregnancy or currently breast feeding Have any other condition that the research team considers a contraindication to participating in the study, e.g. severe cardiac, renal, or pulmonary dysfunction Weight greater than 400 lb for PET and 500 lb for SPECT (limit of the gantry)


eligible ages (years): 0.0-14.0,  All  Pneumococcal Meningitis All children from 0 up to 14 years with diagnosis of confirmed or probable pneumococcal meningitis or with diagnosis of suspected bacterial meningitis without bacterial or viral isolation will be included into the study


eligible ages (years): 18.0-64.0,  All  Back Pain Need a lumbar or cervical myelogram as part of routine care  Not needing a myelogram in the cervical or lumbar spine


eligible ages (years): 8.0-18.0,  All  Migrainous Headache Males or Females age 8-18 years Girls 11 years or older must have a negative urine/serum pregnancy test Diagnosis of pediatric migrainous headache. The for pediatric migraine headache based on the most recent ICHD are listed below. The requirement of 5 attacks (A) will not be required for this study, this making the diagnosis migrainous headache. As described elsewhere in the protocol, this change is required to make the study applicable to ED patients who require treatment before five attacks have occurred  Evidence that headache is due to a secondary underlying disorder based on history or physical examination Pregnant or lactating females Any investigational drug use within 30 days Known to have a contraindication to metoclopramide or valproic acid such as pregnancy, liver disease, hematologic disease, or metabolic disease Have used metoclopramide (or other antidopaminergic medications) or valproic acid within two days of presentation Severe developmental disorders or mental retardation if insufficient information can be obtained to make a clear diagnosis of migraine or judge headache severity If patients re-present to the ED, they can not be re-enrolled


eligible ages (years): 0.0-999.0,  All  Minor Head Injury Traumatic Brain Injury head injury, nausea, vomiting  no head injury


eligible ages (years): 18.0-999.0,  All  Cardiac Arrest Arrhythmia Cardiac Arrest Patients 18 years and older with cardiac arrest in the hospital and successfully resuscitated, or with cardiac arrest out of the hospital and successfully resuscitated ICD patients Patients 18 years and older Who are undergoing elective procedure in the electrophysiology laboratory for placement of a cardiac defibrillator and who will most likely undergo induction of ventricular arrhythmia as part of the procedure  Cardiac Arrest Cardiac arrest and a known pre-existing cerebral pathology such as brain tumor, cerebral hemorrhage, encephalitis or immediately post-op neurosurgery CNS infection Skull defects and scalp diseases that are not amenable to standard EEG testing ICD patients Known pre-existing cerebral pathology such as brain tumor, cerebral hemorrhage, encephalitis or immediately post-op neurosurgery CNS infection Skull defects and scalp diseases that are not amenable to standard EEG testing


eligible ages (years): 20.0-65.0,  All  Post-Traumatic Stress Disorder Patients who are primarily diagnosed with PTSD (Posttraumatic Stress Disorder: 309.81) using DSM-IV-TR criteria. The CAPS-DX (Clinician-Administered PTSD Scale-DX) and M.I.N.I. (The Mini International Neuropsychiatric Interview, Japanese version 5.0.0. [2003]) will be used for diagnosis Pathologic condition: Patients who experienced a motor vehicle accident (MVA) with severe or potential severe physical injury more than 3 months ago but less than 12 months ago Patients aged 20 and <65 at the time of signing the Informed consent Male and female patients Inpatient/outpatient status: Both are permitted Patients who are able to give written informed consent in person (i.e., patients who are capable of giving written informed consent on their own) Patients whose combined score of the CAPS-SX standard B, C, and D is over 50  Patients primarily diagnosed with a DSM-IV-TR Axis I disorder other than PTSD (e.g. major depressive disorder, dysthymic disorder, specific phobia [simple phobia], obsessive-compulsive disorder, panic disorder, etc.) within 6 months of week -4 (start of baseline phase) Patients presenting with a current major depressive episode that preceded the diagnosis of PTSD Patients receiving disability payments due to PTSD or other psychiatric diseases Patients currently engaged in compensation litigation whereby personal gain would be achieved from prolonged symptoms of PTSD or any other psychiatric disorders Patients who meet the DSM-IV-TR for substance abuse or dependence (alcohol or drugs) within 6 months of Week -4 (start of baseline phase) Patients with history of a suicide attempt within 6 months before Week -4 (start of baseline phase), or have, in the opinion of the investigator, "C. high risk of suicide" according to the MINI at Week -4 Patients who are pregnant, lactating or of childbearing potential and are likely to become pregnant Patients receiving electro-convulsive therapy (ECT) prior to Week -4 (start of baseline phase) Patients receiving another investigational product within 12 weeks before Week -4 (start of baseline phase) Patients with a history or complication of manic psychosis


eligible ages (years): 18.0-999.0,  All  Chiari Malformation Type I Age >18 years Clinical Diagnosis of Chiari Type I Malformation Radiogrpahic evidence of downward tonsillar herniation (displacement of the lower part of the cerebellum below the level of the skull) Signed Written Informed Consent  Presence of Hydrocephalus or previous CSF diversion procedure, such as shunt Prior operation on the posterior cranial fossa Inability to understand the informed consent or unwillingness to participate in the study Inability to return for follow-up evaluation 3 months after the surgery Evidence of spinal dysraphism Allergy or history of allergic reaction to Duragen, Duraguard, or their components Pregnancy as documented by a urine or blood test


eligible ages (years): 18.0-75.0,  All  Spinal Procedure Requiring Dura Incision Patients who are scheduled for an elective spinal procedure that requires a dural incision will be considered for study participation Patient requires a procedure that involving surgical wound classification Class 1/Clean (per CDC criteria) Presence of a non-watertight dural closure, either spontaneously or upon Valsala maneuver at 20-25 cm H20 for 5-10 seconds  Active spinal and/or systemic infection Patient requires additional spinal surgery within the study time period Patient has had a previous spinal surgery involving dural exposure and/or entry at the same level(s) as the study procedure Patient has a pre-existing external lumbar CSF drain or internal CSF shunt Patient is participating in a clinical trial of another investigational device or drug Patient with creatinine > 2.0 mg/dL Patient with total bilirubin > 2.5 mg/dL Pregnant or breast-feeding females or females who wish to become pregnant during the length of study participation Patient has been treated with chronic steroid therapy (>4 weeks) unless discontinued more than 6 weeks prior to surgery Patient has documented history or significant coagulopathy with a PTT >35 sec, PT/INR >1.2, receiving asprin, or at the time of surgery


eligible ages (years): 0.167-15.0,  All  Bacterial Meningitis All children aged ≥ 2 months, admitted to Queen Elizabeth Hospital, Blantyre, Malawi, with possible or confirmed acute bacterial meningitis  Age less than two months Trauma Relevant underlying illness such as intracranial shunt, previous neurological disease (cerebral palsy, Down's syndrome) Previous permanent hearing loss (not conductive hearing loss) if known Immunosuppression except HIV infection


eligible ages (years): 18.0-45.0,  All  Familial Mediterranean Fever Fulfilling the Tel Hashomer for the diagnosis of FMF [5] Suffering from episodes of exertional leg pain and or exertional ankle edema 18-45 years old On a stable (≥ 2 weeks) dose of oral colchicine therapy Non-smokers  with known peripheral vascular disease (PVD) and/or multiple risk factors for PVD (such as diabetes, hypertension, hyperlipidemia) Suffering from muscular or neurological diseases not related to FMF With elevated serum creatinine / liver enzymes/ creatine phosphokinase (CPK) levels Suffering from claustrophobia, or with metal fragments in body tissue, or with other contraindications for MRI


eligible ages (years): 3.0-999.0,  All  Pathological Processes in the Posterior Fossa Dura Defects Preoperative Subjects undergoing elective craniotomy / craniectomy for pathological processes in the posterior fossa (such as benign and malignant tumors, vascular malformations, and Chiari 1 malformations) that result in dura defects requiring dura substitution for closure and who are able and willing to comply with the procedures required by the protocol Signed and dated written informed consent from the subject or from his/her legal representative prior to any study-related procedures Age >= 3 years, either gender Intraoperative Surgical Wound Classification Class I and Risk Index Category (RIC) <= 2. Penetration of mastoid air cells during partial mastoidectomy is permitted and will be recorded A patch of autologous fascia or pericranium or suturable collagen-based dura substitute was cut to size and then sutured into the dura defect The hem of native dura exposed along and under the craniotomy edge is wide enough to facilitate suturing and to allow for sufficient surface area for adherence of the investigational product  Preoperative Female subjects who are breastfeeding, pregnant, or intend to become pregnant during the clinical study period Subjects with a dura lesion from a recent surgery that still has the potential for cerebrospinal fluid (CSF) leakage unless it can be expected that the lesion will be excised completely, including all old suture holes Chemotherapy scheduled within 7 days following surgery Radiation therapy to the head scheduled within 7 days following surgery Subjects with severely altered renal (serum creatinine > 2 mg/dL) and/or hepatic function [ALT, AST > 5 x upper limit of norm (ULN)] Evidence of an infection indicated by any one of the following: fever > 101°F, white blood cell (WBC) count < 3500/μL or > 13000/μL, positive blood culture, positive chest X-ray. A positive urine culture (> 10^5 colony-forming units (CFU)/mL) leads to unless acute cystitis is the sole cause. Evidence of infection along the planned surgical path. A WBC count of < 20000/μL is permitted if the patient is being treated with steroids in the absence of all the other infection parameters Conditions compromising the immune system; existence of autoimmune disease Known hypersensitivity to aprotinin or other components of the investigational product Non-compliant or insufficient treatment of diabetes mellitus [glycosylated hemoglobin (HbA1c) > 7.5%]


eligible ages (years): 18.0-75.0,  All  Elective Cranial Procedures With Dural Incision Patient is between 18 and 75 years of age Patient is scheduled for an elective cranial procedure that entails a dural incision Evidence of intraoperative non-watertight closure


eligible ages (years): 6.0-14.0,  All  Status Epilepticus Seizures Children presenting convulsing to the pediatric emergency or developing seizure while in casualty Age 6-14 years  Known hypersensitivity to any benzodiazepine Child has received any parenteral anti-convulsant within 1 hr prior to enrollment Presence of severe cardio-respiratory compromise or cardiac arrhythmias Presence of upper respiratory tract infection Presence of basal skull fracture causing cerebro-spinal fluid (CSF) rhinorrhea


eligible ages (years): 18.0-999.0,  All  Acute Renal Failure SIRS Sepsis Critically Ill Multiple Organ Dysfunction Syndrome Critically ill, postoperative/posttraumatic patients with threatening acute renal failure  Life expectancy < 24 hours Participation in other trials Known or suspected pregnancy


eligible ages (years): 18.0-999.0,  All  Posttraumatic Stress Disorder Diagnosis of Posttraumatic Stress Disorder  Diagnosis of psychosis, drug or alcohol dependency/abuse Unable to fill in questionnaires in Dutch Color blindness (Stroop test)


eligible ages (years): 18.0-65.0,  All  Posttraumatic Stress Disorder willingness to participate in a naturalistic treatment study using paliperidone and in two fear conditioning tests, one at baseline and one at the end of the 6 weeks treatment study We will PTSD subjects on medications (possible medications antidepressants, benzodiazepines) who have no or only partial treatment response. Paliperidone will be added to the existing treatment regime which will remain unchanged during the study period. PTSD subjects will have a minimum score of 50 on the Clinician-Administered PTSD Scale (CAPS; Blake et al, 1995)  a comorbid diagnosis of bipolar illness, schizophrenia or other psychotic disorders, acute or chronic suicidality, acute or chronic unstable medical conditions (including severely impaired hepatic function as indicated with abnormal PT and PTT, abnormal CBC, and liver enzymes more than 50% above the upper normal range, not well controlled blood pressure) current diagnosis of substance abuse or dependence unsuccessful treatment history with paliperidone known hypersensitivity to paliperidone or any of its inactive ingredients administration of any investigational drug up to 90 days before entry into the study intake of Class 1A (e.g., quinidine, procainamid) or Class III (e.g., amiodaronme, sotalol) antiarrhythmic medications, antipsychotics, antibiotics (e.g., gatifloxacin, moxifloxacin) (up to 90 days before entry into the study or during the study) subjects with a positive screen for drugs of abuse no startle or skin conductance response, or excessively high startle response to the startle probe (100 dB acoustic stimuli) during the pretest


eligible ages (years): 16.0-999.0,  All  Rhinitis, Allergic, Perennial Patients of mongoloid race residing in Japan who satisfy all of the following Patients having symptoms of perennial allergic rhinitis of moderate or severe degree, according to the classification of severity in the guidelines for the treatment of nasal allergy (partial revision) as well as a score of at least 4 in the score of 4 nasal symptoms, at the time of obtaining informed consent and during the pretreatment observation period Patients with a positive skin reaction test or specific IgE antibody quantitation, and with a positive cytological examination of nasal discharge (eosinophils) or nasal challenge test Outpatients who are at least 16 years of age at the time of informed consent obtained Male or female Patients who have the ability to give written informed consent (informed consent of the guardian must also be obtained for patients younger than 20 years) Patients who can keep nasal allergy diary without fail  Patients with coexisting tuberculous disease or lower respiratory tract infection, or patients who, at the time of registration, have acute upper respiratory tract infection, acute pharyngitis, acute amygdalitis etc Patients with coexisting infections or systemic mycosis for which there are no effective antibiotics Patients with unhealed nasal septum ulcers, nasal surgery scar, or nasal trauma Patients with a history of hypersensitivity to steroids or mometasone furoate Patients who are pregnant or nursing or who may be pregnant and patients or patients' partners who desire to become pregnant during the study period Patients with severe hepatic, renal, cardiac, hematological disease, diabetes mellitus, hypertension or other serious coexisting diseases and whose general condition is poor Patients also allergic to pollen and the pollen release season occurs during the study period Patients with vasomotor rhinitis or eosinophilic rhinitis Patients with a nasal condition which may interfere with efficacy evaluation of the investigational product Patients who develop disease affecting nasal symptoms during the pretreatment observation period, i.e., during the 7 days before actual registration


eligible ages (years): 16.0-999.0,  All  Perennial Allergic Rhinitis Patients with perennial allergic rhinitis meeting all of the followings Patients with symptoms of perennial allergic rhinitis, the severity of which is moderate or severer according to the severity grading provided in the "Guidelines for the Management of Allergic Rhinitis in Japan" (partly modified) with the 4-nasal symptom score of 4 or over at informed consent and during the pre-treatment observation period Patients with positive reaction to the eosinophil count in nasal discharge or nasal challenge test in addition to the skin test or specific IgE antibody test Outpatients aged 16 years or over at informed consent Patients in either sex Patients (or their legal representatives in case of patients aged under 20 years) capable of giving written informed consent Patients capable of recording nasal allergy diary every day  Patients with a complication of tuberculous diseases or lower respiratory tract infections, and those with a complication of otorhinolaryngeal infections(acute upper respiratory tract inflammation, acute laryngopharyngitis, acute tonsillitis, etc.) requiring treatments judged by the investigator (subinvestigator) at the time of enrollment to randomization Patients with a complication of infection or systemic mycosis for which no effective antibiotics are available Patients with a complication of recurrent epistaxis Patients with uncured nasal septal ulcer, operated nose or nasal trauma Patients with a history of hypersensitivity to steroids and any ingredients of the study drugs Pregnant, lactating or possibly pregnant patients or the patients who themselves or whose partners wish to become pregnant during the study Patients with severe hepatic or renal disorder, heart or blood disease, diabetes mellitus, hypertension, or other serious complication, suffering from problems with systemic condition Patients who have pollens as multiple allergens and the period from 7 days before enrollment to randomization to completion of the treatment period coincides with the period of scattering of relevant pollens Patients with a complication of vasomotor rhinitis or eosinophilic rhinitis Patients with a complication of a nasal disease (infectious sinusitis, hypertrophic rhinitis, acute or chronic rhinitis, nasal polyps, or septal deviation) which may interfere with efficacy evaluation of the study drugs


eligible ages (years): 18.0-999.0,  All  West Nile Neuroinvasive Disease West Nile Virus Infection Encephalitis Meningitis Acute Flaccid Paralysis West Nile Fever Provide written informed consent Be >=18 years of age at the time of enrollment Have West Nile Fever defined as temperature >38°C, headache, AND positive diagnostic test for WNV Ribonucleic acid or Immunoglobulin M with serum or cerebrospinal fluid (CSF) OR have West Nile Neuroinvasive Disease (includes neurological signs and/or symptoms of West Nile meningitis, encephalitis, and/or acute flaccid paralysis), defined as • West Nile encephalitis (must meet a and b below) Encephalopathy (depressed or altered level of consciousness, lethargy, or personality change lasting 24 hours) CSF pleocytosis >=5 cells/mm^3 AND/OR


eligible ages (years): 18.0-999.0,  All  Brain and Central Nervous System Tumors Breast Cancer Metastatic Cancer Meets 1 of the following Diagnosis of metastatic breast cancer with evidence suggestive of carcinomatous meningitis, with or without brain metastasis Other type of cancer with evidence suggestive of carcinomatous meningitis Meningeal syndrome without context of cancer No other prior cancers Not pregnant or nursing No prior intrathecal treatment At least 4 weeks since prior interferon No concurrent participation in another clinical trial


eligible ages (years): 12.0-999.0,  All  Vasomotor Rhinitis Diagnosis of VMR with at least 2 years of chronic non-allergic rhinitis Negative skin tests to a panel of allergens and positive histamine test within last 2 years History of symptoms related to defined VMR triggers  Nasal disorder, surgery, or concurrent disease that could interfere with evaluation of study medications Bacterial or viral infection within 14 days of first visit. Diagnosis of acute sinusitis within 30 days of first visit Chronic use of drugs that can cause rhinitis


eligible ages (years): 5.0-15.0,  All  Rhinitis, Allergic, Perennial Pediatric subjects with perennial allergic rhinitis who satisfy all of the following main Subjects having symptoms of perennial allergic rhinitis of moderate to severe degree, after the pretreatment observation period Subjects confirmed to be allergic to non-seasonal environmental antigens (e.g., house dust-mite antigen) Male or female outpatients aged 5 to 15 years at the time of providing informed consent  Subjects for whom any of the main below is applicable will not be registered in this study Subjects with coexisting tuberculous disease or lower respiratory tract infection and subjects who have a nasopharyngolaryngeal infection (acute upper respiratory tract infection, acute pharyngolaryngitis, or acute tonsillitis, etc.) requiring treatment at the time of registration Subjects with coexisting infections or systemic mycosis for which there are no effective antibiotics Subjects with repeated epistaxis Subjects who have nasal septum ulcers, nasal surgery, or nasal trauma, which have not healed Subjects with severe hepatic, renal, cardiac, hematological disease, diabetes mellitus, hypertension, or other serious coexisting diseases and whose general condition is poor Subjects with complication of vasomotor rhinitis or eosinophilic rhinitis Subjects with nasal conditions (infectious sinusitis, hypertrophic rhinitis, acute or chronic rhinitis, nasal polyps, septal deviation, etc.) which may interfere with the evaluation of the efficacy of the study drug


eligible ages (years): 0.0-999.0,  All  Brain Injuries, Traumatic Injuries, Acute Brain TBI (Traumatic Brain Injury) Adults and children with physical trauma who: 1) are transported directly to or are transferred to a level I TC by participating EMS agencies, 2) have hospital diagnosis(es) consistent with TBI (either isolated or multisystem trauma that includes TBI), and 3) meet at least one of the following definitions for severe TBI: a) last prehospital GCS or first hospital/trauma center GCS <9; b) AIS-head of ≥3, c) CDC Barell Matrix-Type 1, d) undergo prehospital ETI, nasal intubation, or cricothyrotomy  Patients with brain injury from: 1) non-mechanical mechanisms (e.g., drowning); 2) choking, primary asphyxiation, or strangulation; 3) environmental injury (e.g., hyperthermia); 4) poisoning (e.g., drug overdose, carbon monoxide, insecticides); 5) intracranial hemorrhage of non-traumatic origin; 6) other non-traumatic, acute neurological emergencies (e.g., bacterial meningitis)


eligible ages (years): 18.0-999.0,  All  Cerebrospinal Fluid Leaks Main (Positive response) • Is the surgical approach/procedure consistent with skull base surgery? I.e. one of the following Lateral approach to the foramen magnum: Far lateral, extreme lateral, anterolateral, posterolateral Approach to the jugular foramen: Infratemporal, juxta condylar, transjugular Approach to the cerebello pontine (CP) angle and petrous apex retrosigmoid Approach to the middle fossa: Subtemporal (+/ petrous apex drilling), pterional approach (any fronto temporal approach +/ orbitozygomatic deposition) Approach to the anterior fossa: Subfrontal (uni or bilateral) Approach to the midline posterior fossa  (Negative response) Has the patient been subject to neurosurgery involving opening of the dura mater within the last 3 months? Is the patient anticipated to undergo any additional neurosurgery involving opening of the dura mater which may affect the efficacy evaluation (e.g. re-operation or anticipation to undergo several neurosurgeries) before the Efficacy Follow-up Week 7±1 week? Is the patient anticipated to undergo any additional neurosurgery involving opening of the dura mater which may affect the safety evaluation (e.g. re-operation or anticipation to undergo several neurosurgeries) before the Safety Follow-up Week 28±2 weeks? The surgical approach/procedure is consistent with any transcranial or transfacial or combination of transcranial transfacial approaches with wide defect in the skull base? I.e. any of the following Trans basal approach Total petrosectomy Trans facial approach Trans sphenoidal approach


eligible ages (years): 18.0-50.0,  All  Perennial Rhinitis Seasonal Rhinitis All patients have to sign the informed consent or give verbal confirmation prior to their in the study Outpatient (external) male or female over 18 years and under 50 years Patients with active rhinitis (anterior or posterior rhinorrhea, sneezing, nasal congestion and itching) persistent (≥ 4 days a week for 4 consecutive weeks) or intermittent (< 4 days a week for ≤ 4 consecutive weeks) Patient with medical history of rhinitis 2 years prior to their participation in this study and whose nasal symptoms have been severe enough to require continuous or intermittent treatment (it requires a patient's symptoms need treatment at least for a 4 weeks period) Patient with the ability to understand the risks and benefits requirement while participating in the study and is able to accomplish the study treatment and with filling questionnaires and patient's diaries  Patient with other nasal disease including: nasal polyps or nasal trauma recent Patient with intranasal malformations (cysts and fistulas of the nose dorsum, prenasal space malformation, midline dystrophy, arrhinea, abnormalities of the tear ducts), or other conditions such as; recent nasal biopsy, drug rhinitis Non-controlled asthma or who were under systemic corticosteroid treatment Patient with Chronic Obstructive Pulmonary Disease Medical history of respiratory infection or other disease including bronchitis, pneumonia, common cold, acute or chronic sinusitis, influenza, etc. within 30 days prior to its in the study Patient receiving antibiotic therapy for any acute illness during the past 14 days Patient vaccinated against pneumococcus, H1N1 & seasonal influenza (past 30 days) Patient required initiation or dose escalation immunotherapy. Immunotherapy is permitted if started 90 days ago and the patient received a stable dose during the last 30 days Patient has participated in another research study within 30 days preceding this visit Patient with medical history of hypersensitivity to steroids or any excipients of this class of drugs


eligible ages (years): 7.0-15.0,  All  Perennial Allergic Rhinitis Patients aged between 7 and 15 years Patients with a weight of at least 20 kg Patients who have received a diagnosis of perennial allergic rhinitis according to the diagnostic Patients with a mean rhinorrhea score of at least 2 and a mean total score for the three major nasal symptoms [sneezing, rhinorrhea, and nasal congestion] of at least 4 on the basis of symptoms recorded in the nasal allergy diary during the observation period  Patients with vasomotor rhinitis or eosinophilic rhinitis Patients who have concurrent nasal disease that may affect the efficacy of TAU-284 Patients with a history of any of the nasal surgical procedures Patients who have a positive result for pollen antigens which are dispersed during the study period Patients who have a positive result for dog dander or cat dander antigen Patients with current or previous history of drug allergy Patients who concurrently have renal function abnormalities that may cause safety problems


eligible ages (years): 0.0-18.0,  All  Head Trauma Children who had a radiography for head trauma


eligible ages (years): 50.0-999.0,  All  Seizures Pneumococcal Meningitis Adult patients > or = 50 years old Diagnosed of pneumococcal meningitis due to clinical characteristics plus a positive CSF Gram stain and/or a detection of pneumococcal antigen or PCR Suspected pneumococcal meningitis since it is an episode related to otitis, pneumonia, sinusitis or pericranial fistula or in patients with known risk factors such as myeloma or splenectomy  To have seizures prior to arrive to the hospital or the in the study Pregnancy or breastfeeding To have conduction abnormalities in ECG History of allergy or intolerance to phenytoin Patients with meningitis as a complication of neurosurgical procedures Epileptic patients taking usually anticonvulsivants Refusal by the patient or family to participate and/or to sign the informed consent


eligible ages (years): 18.0-999.0,  All  Post-lumbar Puncture Headache Backache All adult patients (>= 18 years old) referred at the Neurological Day Center to get a lumbar puncture  Contraindication to get a lumbar puncture


eligible ages (years): 18.0-50.0,  All  Meningococcal Meningitis Meningococcal Infections Willing and able to give informed consent and comply with all aspects of the evaluation after the nature of the study is explain For the purpose of this study, a healthy volunteer is defined as healthy male or female, with no significant chronic conditions Age 18 to 50 years old Either gender. Abstinence or use of contraception during the eight weeks after vaccination will be required for non menopausal (< two years post-menopause) or non surgically sterile women Persons with antibody titer(s) of <2 µg/mL to serogroup(s) A, C, Y, or W-135 polysaccharides as measured by ELISA  Age less than 18 years or over 50 years History of Guillain-Barré syndrome (GBS) Pregnancy or lactation History of meningococcal meningitis History of invasive (clinical or laboratory diagnosis) meningococcal disease History of meningococcal meningitis vaccination Screening laboratory abnormalities (in the opinion of the Investigator) that would raise safety concerns for participation in the study Use of immunosuppressive drugs within 30 days prior to study enrollment, not including topical or inhaled steroids/cytotoxic agents History of anaphylactic shock, asthma, urticaria, or other allergic or hypersensitivity reactions following vaccination History of severe allergic disorders or autoimmune connective tissue disorders, including rheumatoid arthritis. A high sensitivity C-Reactive Protein (CRP) test at screening will be used as part of the assessment of autoimmune disorders by the Principal Investigator


eligible ages (years): 18.0-50.0,  All  Post Dural Puncture Headache 50 years old Undergoing diagnostic LP for any indication for the first time  COPD Any known chronic pulmonary disease Acute febrile illness Persistent headaches Known sensitivity to Benzodiazepines Current or prior substance abuse disorder Cognitive decline


eligible ages (years): 18.0-30.0,  All  Schistosomiasis Bilharziasis Urinary Schistosomiasis All subjects had to meet the study within 21 days prior to treatment Caucasian volunteers No smoker biological parameters (haematological, biochemical, renal and hepatic) in normal range Health Insurance sign inform consent  inflammatory or immunological pathology such as atopic diseases, evidence of inflammation or acute infection (including positive serology to viral hepatitis B and C or HIV) any immunological deficiency any clinically relevant alcohol or drug use (cannabis, opiates, cocaine, amphetamines, benzodiazepines, nicotine, barbiturates, meprobamate or antidepressant drugs according to urine drug and metabolites screen) current immunosuppressor treatment any other medication use within 2 weeks before the study any vaccination within the last 6 months no antibodies against Sh28GST protein


eligible ages (years): 0.25-16.0,  All  Meningitis Age > 3 months and < 16 years Bacterial meningitis Written parental (or appropriate legal representative) informed consent prior to study  Gram-negative bacteria in the CSF Creatinine clearance < 80ml/min/1.73m2 Creatinine phosphokinase level > 2x upper age related norm Known allergy or hypersensitivity to daptomycin Known clinical significant cardiovascular, pulmonary, renal, hepatic, gastrointestinal, endocrine, hematologic, autoimmune disease, or primary immunodeficiency Height and weight below 3rd or above 95th percentile History of, or current muscular disease Underlying neurological disease with disruption of blood brain barrier Epilepsy Muscular weakness, history of peripheral neuropathy, or Guillain-Barré syndrome


eligible ages (years): 0.167-15.0,  All  Bacterial Meningitis The study entry is assessed for all children at age 2 months years who present at these centers with the symptoms and signs suggestive of BM, and to whom lumbar puncture is performed All patients whose cerebrospinal fluid (CSF) turns out to be cloudy, positive by Gram staining or latex agglutination, or shows at least 50 leukocytes per mm3, will be enrolled in the study Participants  Trauma, or relevant underlying illness such as intracranial shunt, previous neurological abnormality (cerebral palsy, Down's syndrome, meningitis) Previous hearing impairment (if known) Immunosuppression, except HIV infection More than one parenteral dose of a pretreatment antimicrobial. Children with oral antimicrobials are included, this information being marked in the sheet Active tuberculosis (if tuberculotic meningitis is diagnosed during trial, it will be included in intention-to-treat (ITT) analysis) Known hepatic disease


eligible ages (years): 0.0-0.247,  All  Meningitis Informed consent form signed by the parents/carers Chronological age below 90 days inclusive The presence of clinical signs consistent with BM (hyperthermia or hypothermia or temperature instability PLUS 1 or more neurological findings among coma, seizures, neck stiffness, apnoea, bulging fontanelle) OR CSF pleocytosis (≥ 20 cells/mm3) OR a positive Gram stain of CSF  Presence of a CSF device Proven viral or fungal meningitis Severe congenital malformations if the infant is not to expect to survive for more than 3 months Other situations where the treating physician considers a different empiric antibiotic regimen necessary Known intolerance or contraindication to the study medication Participation in any other clinical study of an investigational medicinal product Renal failure and requirement of haemofiltration or peritoneal dialysis Meningitis with an organism known to be resistant to meropenem


eligible ages (years): 18.0-65.0,  All  Acute Migraine Willing and able to provide written informed consent prior to participation in the clinical investigation Male or female aged between 18 and 65 years Diagnosed as suffering from migraine with or without aura according to IHS classification (ICHD-II) Reported history of 2 to 6 migraine episodes per month during previous 3 months, confirmed during a prospective baseline period of one month Reported history of no less than 50% of migraine episodes involving moderate or severe pain intensity, confirmed during a prospective baseline period of one month Reported history of at least 48 hours of freedom from headache between migraine attacks, confirmed during a prospective baseline period of one month Reported history of the majority of untreated migraine attack durations lasting 8 hours or more Onset of migraine headache occured before age 50 Reported history of migraine for more than one year Able and willing to maintain current preventive headache medication regimen(s) (no change in type, frequency or dose) from baseline screening visit to 2 weeks post-treatment  Reported history of 15 or more headache days per month (i.e. headaches of any kind), confirmed during a prospective baseline period of one month Reported frequency of non-migraine headaches exceeding 6 days per month, confirmed during a prospective baseline period of one month Unable to distinguish between migraine headaches and other headache types at the onset of a migraine attack Treatment with Botox received within 6 months of the screening visit, or between the screening and treatment visit Previously treated with an implantable stimulator or any implantable devices in the head and/or neck Diagnosed as having a pronounced anterior septal deviation History of sinus surgery, transphenoidal surgery for pituitary or other lesions or CSF rhinorrhea Fitted with a pacemaker /defibrillator Previously treated with radiation to the face Ongoing bacterial infection in the nasal cavity


eligible ages (years): 0.0-999.0,  All  Streptococcus Pneumoniae Neisseria Meningitidis Haemophilus Influenzae Subjects who the investigator believes can and will comply with the requirements of the protocol or subjects who the investigator believes that parent(s)/Legally Acceptable Representative(s) [LAR(s)] can and will comply with the requirements of the protocol Written informed consent obtained from the subject/from the parent(s)/LAR of the subject A male or female subject who visits the hospital with suspected bacterial meningitis CSF sample taken as part of routine practice  Child in care


eligible ages (years): 18.0-999.0,  All  Meningitis, Bacterial Positive CSF culture and/or positive soluble antigens in CSF with or without a cell reaction Positive PCR in CSF Purpura fulminant (with or without positive CSF culture) Positive PCR in blood and/or positive blood culture AND CSF cell reaction  Age less than 18 years old Refusal to participate


eligible ages (years): 0.0-999.0,  All  Pneumonia, Bacterial Pneumonia, Viral Meningitis, Bacterial Pneumonia surveillance resident of Tône sanitary district requiring hospitalisation for at least one night for clinical pneumonia syndrome hospitalised in a study site during the study period  absence of informed consent by patient or legal tutor Meningitis surveillance resident of Tône sanitary district presenting clinical signs of acute bacterial meningitis hospitalised in a study site during the study period absence of informed consent by patient or legal tutor


eligible ages (years): 18.0-999.0,  All  Stress Disorders, Post-Traumatic Myocardial Infarction Age over 18 years STEMI (ST-elevated myocardial infarction) or non-STEMI Stable circulatory condition Numeric Rating Scale (NRS) (0-10): a score of at least 5 for "pain (during MI)" plus a score of at least 5 for "fear of dying (until admission to the CCU)" and/or "making sorrows and feeling helpless (when being told about having MI)" Written informed consent  Participating in any other randomized-controlled trial run by the Cardiology Department of the University Hospital of Bern Emergency coronary artery bypass graft surgery Comorbid serious disease likely to cause death within 1 year Current clinically severe depression Not fully oriented to the situation, person, and place Cognitive impairment according to an adapted short version of the Mini-Mental State Examination Insufficient knowledge of German language in reading and understanding Affirmation of suicidal ideation in the last two weeks


eligible ages (years): 30.0-70.0,  All  Posttraumatic Stress Disorder PTSD as determined by the Structural Clinical Interview for DSMIV (SCID) interview of PTSD and the Clinical Administered PTSD Scale (CAPS) Veteran with history of active duty service and currently discharged from active duty service Free of psychotropic medication for four weeks before the study  History of shrapnel or other foreign bodies which would preclude MRI scanning Meningitis Traumatic brain injury Neurological disorder or organic mental disorder History of loss of consciousness Current or lifetime history of alcohol abuse or substance abuse or dependence base on the SCID Current or lifetime history of schizophrenia, schizoaffective disorder, or bulimia based on the SCID History of serious medical or neurological illness, such as cardiovascular, gastrointestinal, hepatic, renal, neurologic or other systemic illness Evidence of a major or neurological illness on physical examination or as a result of laboratory studies positive urine toxicology screen


eligible ages (years): 18.0-65.0,  All  Tuberculous Meningitis Age 18 years or older Probable/possible tuberculosis meningitis using uniform case definition Agree to participate in the study  Patient with antituberculosis treatment within last 2 weeks Increase liver function >5x upper limit of normal Pregnancy


eligible ages (years): 8.0-17.0,  All  Traumatic Brain Injury Brain Concussion Children aged between 8 and 17 years old. This will be limited to this small spectrum of age to insure better homogeneity in the evaluation of the participants and streamlining of outcome measures. Also, this is the age group for which our measurement tool has been validated Occurrence of a mTBI as defined by the presence of a head trauma, a Glasgow coma scale of 13 to 15 and at least one of the three following criteria4  Any period of loss of consciousness Any loss of memory for events immediately before or after the accident Any alteration in mental state at the time of the accident (eg, feeling dazed, disoriented) And the absence of the following Post-traumatic amnesia greater than 24 hours Glasgow Coma Scale < 13, 30 minutes post accident The trauma occurred in the preceding 24 hours  Inability to obtain a proper written informed consent (language barrier, absence of a parental authority, developmental delay, intoxication, patient too confuse to consent according to the treating physician) Known allergic reaction or intolerance to ondansetron. 3. Known rhythm or cardiac problem, or history of sudden death in the proximal family 4. Patients who are taking a medication which could increase the QT interval. 5. Patients who received ondansetron in the previous 24 hours 6. Any abnormality on radiological studies, including any bleeding in the brain or skull fracture Multi-system injuries with treatment requiring admission to hospital or procedural sedation in the ED


eligible ages (years): 7.0-15.0,  All  Perennial Allergic Rhinitis Patients aged between 7 and 15 years Patients who have received a diagnosis of perennial allergic rhinitis according to the diagnostic Patients with a mean rhinorrhea score and a mean sneezing score of at least 2 on the basis of symptoms recorded in the nasal allergy diary during the observation period etc  Patients with vasomotor rhinitis or eosinophilic rhinitis Patients who have concurrent nasal disease that may affect the efficacy of TAU-284 Patients with a history of any of the nasal surgical procedures Patients who have a positive result for pollen antigens which are dispersed during the study period Patients who have a positive result for dog dander or cat dander antigen and have a chance to touch dogs or cats Patients with current or previous history of drug allergy Patients who concurrently have renal function abnormalities that may cause safety problems etc


eligible ages (years): 18.0-55.0,  All  Meningococcal Meningitis Meningococcal Infections (IC) Participant is willing and able to give informed consent and comply with all aspects of the evaluation after the nature of the study is explained Male or female, aged 18 to 55 years old In general good health with no significant chronic or acute conditions that would interfere with immune response or expected Adverse Event (AE) evaluation in the opinion of the investigator as determined by Medical history and/or History-directed physical examination Abstinence or use of effective contraception by the participants or their partners during the trial and continuing for four weeks after vaccination will be required for males or female participants of child bearing potential Able (in the opinion of the investigator) to comply with all study requirements  (EC) Unwilling or unable to understand study requirements and give written informed consent for the study Prisoners History of Guillain-Barré syndrome (GBS) Pregnancy (confirmed by positive pregnancy test) or lactation Previous diagnosis of laboratory confirmed meningococcal disease Previous meningococcal meningitis vaccination in the last five years Laboratory abnormalities that are considered Grade 2 or higher (based on AE, ranges as described in the protocol appendix) that in the opinion of the Investigator would raise safety concerns for participation in the study or interfere with evaluation of study objectives, or abnormalities >2 times the Upper Limit of Normal range (ULN) Known or suspected autoimmune or connective tissue disorders, including rheumatoid arthritis and congenital or acquired immunodeficiency. Does not mild to moderate seasonal/perennial allergies treated with over the counter antihistamines Use of systemic immunosuppressive drugs or therapy within 6 months prior to study enrollment, not including topical or inhaled steroids/cytotoxic agents. Includes anti-cancer chemotherapy, radiation, and long term systemic corticosteroid therapy. History of anaphylactic shock, severe asthma, urticaria, or other allergic or hypersensitivity reactions following vaccination or known hypersensitivity to any vaccine component


eligible ages (years): 50.0-999.0,  All  Low Trauma Non Vertebral Fracture Patients of more than 50 years old Low trauma non vertebral fracture Ambulatory patient Direct access to mobile phone (or access with the help of a close person) and ability to communicate via SMS Patient who doesn't oppose to his participation in the study Affiliation to the social security  Patients hospitalized for the fracture in the orthopaedics department because these more severe patients have a systematic screening and management of osteoporosis Fractures whose location is not suggestive of osteoporotic fracture (cervical spine, skull, hands, fingers, toes) Pathological fractures (cancer or myeloma) Traumatic fractures Severe alterations of cognitive functions Resident subjects except Paris and the surrounding area


eligible ages (years): 12.0-999.0,  All  Perennial Allergic Rhinitis Diagnosed with perennial allergic rhinitis Outpatient  Lower respiratory tract infection or nasopharyngolaryngeal infection (acute upper respiratory tract infection, acute pharyngolaryngitis, or acute tonsillitis, etc.) Coexisting infections or systemic mycosis for which there are no effective antibiotics Asthma complication under treatment Nasal septum ulcers, nasal surgery, or nasal trauma, which has not healed Vasomotor rhinitis or eosinophilic rhinitis Nasal conditions (infectious sinusitis, hypertrophic rhinitis, acute or chronic rhinitis, nasal polyps, septal deviation, etc.) which may interfere with the evaluation of the efficacy of the study drug History of hypersensitivity to antihistamines or study drug Currently receiving treatment with another investigational drug or has received an investigational drug in the past 3 months Has started specific desensitization therapy or nonspecific allassotherapy (Histaglobin, vaccine therapy, etc.) or who had discontinued such therapies within 90 days (3 months) before the day of obtaining informed consent Severe hepatic, renal, cardiac, hematological disease, or other serious coexisting diseases and whose general condition is poor


eligible ages (years): 18.0-999.0,  All  Nasal Septum Deviation Headache All patients older than 18 years whom underwent sinuses or facial tomography  Patients with clinical history of trauma


eligible ages (years): 18.0-85.0,  All  Primary Headache 85 years old Benign headache Physician intends to treat headache pain in the ED with either droperidol, prochlorperazine, or a parenteral narcotic  Unable to provide informed consent Headache due to trauma, subarachnoid hemorrhage, meningitis, intracerebral bleed, cranial tumor, sinusitis, dental pathology, temporomandibular joint dysfunction, glaucoma, or systemic infection Known renal impairment Known hepatic impairment A history of coronary artery disease, peripheral vascular disease, or cerebrovascular disease Perforated ear drum Pregnant


eligible ages (years): 0.0-999.0,  All  Inner Ear Malformations Must have an inner ear malformation Must meet the for cochlear implantation  Prior cochlear implantation surgery


eligible ages (years): 18.0-999.0,  All  Traumatic Brain Injury Severe or moderate brain trauma subjects with need of ICU care Glasgow Coma Score (GCS) ≤ 8 after the primary stabilization has been performed in the field (= patient not hypoxic or hypotensive) and at least 30 min interval from the moment of injury GCS 9 and the patient is deteriorating The patient has GCS ≤ 13 and has other injuries, which require interventions for hemodynamic or ventilatory incidents The patient is in urgent need of neurosurgery (craniotomy, impression skull fracture, severe haemorrhagic contusion, or ICP measurement) Moderate or mild brain trauma not in need of ICU care All other patients who fulfil the diagnostic for an acute TBI but without any  defined below Age < 18 years at study entry Blast-induced TBI Perforating or penetrating mechanism of TBI Unable to live independently because of a brain disease (= e.g. people with moderate dementia, Down's syndrome, cerebral palsy etc.) or other medical cause before the injury TBIs or suspected TBIs not needing cranial CT imaging (excludes the mildest TBIs with negligible risk for incomplete recovery) for control subjects Age ≥ 18 years at study entry Acute orthopaedic non-trivial trauma that needs either surgery or conservative measures and clinical follow-up (including mere superficial soft tissue injuries) for control subjects


eligible ages (years): 0.0-18.0,  All  Head Injury Parents and their child, seeking care for a child who Is < 18 years of age Had blunt trauma above the eyebrows (not isolated to face or eyes) Is positive for at least 1 of the clinical prediction rule predictors described below Predictors for children < 2 years of age Severe mechanism (PECARN definition)* Loss of consciousness > 5 seconds Acting abnormally per parent Initial ED GCS < 15 by attending (or CT decision-maker) Other signs of altered mental status (PECARN definition) Presence of occipital, temporal or parietal scalp hematoma Palpable skull fracture or unclear if skull fracture predictors for children 2-18 years of age Severe mechanism (PECARN definition)* Any loss of consciousness Any vomiting since the injury Severe headache in ED Initial ED GCS < 15 by attending (or CT decision-maker) Other signs of altered mental status (PECARN definition)** Any sign of basilar skull fracture Clinicians attending physicians and fellows or midlevel providers caring for children with head trauma  Parents of children with GCS scores < 15 Evidence of penetrating trauma, signs of basilar skull fracture, or depressed skull fracture on physical examination Brain tumors Ventricular shunts Bleeding disorder Pre-existing neurological disorders complicating assessment Neuroimaging at an outside hospital before transfer Signs of altered mental status (agitation, somnolence, repetitive questioning, or slow response to verbal communication) Syncope or seizure disorder preceded (led to) head trauma or seizure post head trauma


eligible ages (years): 5.0-999.0,  All  Concussion Stress Disorders, Post-Traumatic All patients will be recruited from the Bellevue Hospital Emergency Services (Emergency Department and Trauma Bay) or from among inpatient populations at Bellevue Hospital. They will need to be consentable and able/willing to participate and meet for distribution into one of the three subject populations (structural TBI, non-structural TBI, injured/non-TBI) described here mild to moderate structural traumatic brain injury (TBI) as evidenced by CT scan demonstrating the presence of hemorrhage (subdural, epidural, subarachnoid or intraparenchymal), brain contusion, or skull fracture non-structural TBI(concussion), meaning no signs of structural injury on imaging; however, they complain of usual brain injury symptoms such as headache, dizziness, cognitive impairments, etc., A subject with a traumatically induced physiological disruption of brain function, manifested by >1 of the following Any period of loss of consciousness (LOC) Any loss of memory for events immediately before or after the accident Any alteration in mental state at the time of accident (i.e. feeling dazed, disoriented, or confused) Focal neurological deficit(s) that may or may not be transient, but where the severity of the injury does not exceed the following Loss of consciousness of approximately 30 minutes or less After 30 minutes, an initial Glasgow Coma Scale (GCS) of 13-15 Posttraumatic amnesia (PTA) not greater than 24 hours  Subjects that receive minor penetrating trauma insufficiently traumatizing to result in sufficient sequelae will be excluded Subjects suffering burns, anoxic injury or multiple/extensive injuries resulting in any medical, surgical or hemodynamic instability will also be excluded Particularly for the purposes of eye tracking all subjects that are blind (no light perception), are missing eyes, do not open eyes will be excluded from the research It is pertinent that subjects be able to detect light and have both eyes in order for the eye tracking data to be effective and significant Any physical or mental injury or baseline disability rendering task completion difficult will be excluded, also inability to participate in longtitudinal care, or obvious intoxication or blood alcohol level greater than 0.2 Pregnant individuals and prisoners will also be excluded from the study


eligible ages (years): 18.0-55.0,  All  Cephalalgia Complain about cephalalgia Age 28 to 55 years  Fever > 38,0 °C History of breath disease, long term use of oxygen therapy, chronic obstructive pulmonary disease, dyspnéa History of cranial traumatism, heart attack, cerebrovascular accident <3 month Inability to read or understand french Pregnancy


eligible ages (years): 2.0-5.0,  All  Cold for patients with common cold Male or female at least 2 but not older than 5 years of age at screening Have a diagnosis of a common cold defined as presence of acute onset of rhinorrhea (within 48 hours of screening visit) and at least 1 of the following Presence of swollen nasal membranes characteristic of a common cold on examination at screening Presence of fever up to 102°F (oral or equivalent) within 48 hours of visit (may be taken at home/away from the clinic) or at time of screening Capability of parent/legal guardian to read and understand the informed consent, record trial diary information, administer trial drug and read and understand trial assessment questionnaire for patients with allergies Male or female at least 2 but not older than 5 year of age Have a diagnosis of seasonal or perennial allergic rhinitis defined as having both of the following Positive skin or Radioallergosorbent test (RAST) test to a relevant allergen within 12 months of screening or at the screening visit. For the purpose of this trial a positive skin test is defined as wheal diameter that is at least 3 mm greater than the negative control  for both common cold and allergy Significant cardiovascular, renal, hepatic, endocrine, metabolic, neurologic or other systemic disease. A significant disease was defined as one which, in the opinion of the Investigator, either put the patient at risk because of participation in the trial or influenced the results of the trial or the patient's ability to participate in the trial Presence of rales or rhonchi suggestive of a lower respiratory tract infection An oral (or equivalent) temperature higher than 102°F Presence of otitis media Be initiating or advancing immunotherapy regimen during the course of this trial. Patients receiving a maintenance dose of immunotherapy are eligible Known intolerance to anticholinergics of hypersensitivity to benzalkonium chloride Excluded medications prior to Visit 1 and during the trial included 24 hours before Over-the-counter decongestants or nasal/ocular cromolyn


eligible ages (years): 18.0-50.0,  All  Healthy Volunteers Male or female of any race 50 years old, inclusive Females: negative urine pregnancy test on the day of study participation (prior to exposure to hypoxia) Completed within the last year: physical exam by a licensed physician, physician assistant (PA), or advanced practice nurse; including a 12 lead ECG, a medical history, and blood test (complete blood count and sickle cell trait/disease screening) Meets specific demographic requirements for the monitoring device under study Willing and able to provide written informed consent Able to participate for the duration of the evaluation  A room-air baseline % modulation < 1.5% on all four fingers on the test hand Under 18 years or over 50 years of age Pregnant and/or lactating women Hypertension: on three consecutive readings, systolic pressure greater than 145 mm Hg or diastolic pressure greater than 90 mm Hg Ventricular premature complexes (VPC's) that are symptomatic or occur at a rate of more than four per minute History of seizures (except childhood febrile seizures) or epilepsy History of unexplained syncope Daily or more frequent use of anxiolytic drugs (benzodiazepines) for treatment of anxiety disorder Recent history of frequent migraine headaches: average of two or more per month over the last year Compromised circulation, injury, or physical malformation of fingers, toes, hands, ears or forehead/skull or other sensor sites which would limit the ability to test sites needed for the study. (Note: Certain malformations may still allow subjects to participate if the condition is noted and would not affect the particular sites utilized.)


eligible ages (years): 18.0-999.0,  All  Spontaneous Intracranial Hypotension years or more No contraindication for BPE Severe or moderate headache within 15 min standing, mild or no headache after 15 min bed rest Headache from 5 to 28 days Normal or evidence of low CSF on MRI Signed informed consent  Known dural leak in the previous 2 months Abnormal MRI First BPE for SIH The patient has participated in another clinical trial than can interact with the evaluation Contraindication of Trendelenburg position